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INTRODUCTION  
Simvastatin is 2, 2 –dimethyl butanoic acid (1S, 3R, 7S, 
8S, 8aR) – 1, 2, 3, 7, 8, 8a-hexahydro-3, 7-d imethyl-8-[2-
[(2R,4R) tetrahydro -4- hydroxyl- 6 -oxo-2H pyran-2-
yl]ethyl-1-naphthalenyl ester
1,2
 belongs to the group of 
cholesterol-lowering lactones known as statins which, in 
2007, were identified as being the most widely p rescribed 
drugs in the world. Statins lower cholesterol by inhibit ing 
the synthesis of mevalonic acid, which is a key precusor in 
cholesterol synthesis. SMT, a lipid lowering agent that is 
derived synthetically from a fermentation product of 
Aspergillus terreus has been found to lessen both normal 
and elevated LDL-C concentrations.  
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Figure 1: Chemical structure of Simvastatin 
The drug is officially listed in 2004 United States 
Pharmacopocia and the official method of its 
determination is UV-spectrophotometry
3-5
, and various 
other methods are HPTLC
6
, miscellar eletrokinetic 
chromatography and voltammetry 
7 
have been reported for 
the assay of SMT in pharmaceuticals . The method 
development bottleneck result from the requirement to 
generate a quantitative and qualitative profile of 
impurities, enabling the reporting of the identity of each 
chemical moiety
8
. Two official methods utilising HPLC 
GRADIENT methodology are reported in European 
Pharmacopoeia (EP) and United State Pharmacopoeia 
(USP) 
9, 10
. 
                                
MATERIALS AND METHODS   
All the reagents used were of HPLC grade and analytical 
grade and were purchased from Merck Chemicals, India. 
Reference standard of Simvastatin was supplied as gift 
sample from Sun Pharmaceutical Laboratories Limited, 
Mumbai with purity of 99.987%.  
 Preparation of buffer solution:  
Mix 5mL of glacial acid in 1000mL of milli Q water. 
To 1000mL of 5mL g lacial acetic acid solution, add 
0.94gm of 1-Hexane sulphonic acid 
anhydrous.sonicate to dissolve. 
 Preparation of Mobile phase: 
The mobile phase is prepared by mixing buffer: 
methanol in the ratio of 96:4 Filtered and degas it  
 Chromatographic Run: 
Load the standard solution of simvastatin in the 
injector, enter the HPLC parameters as per (Table: 
1), save the method, inject and run for 20min.  
 Standard preparation of simvastatin 
Accurately weigh and transfer about 20 mg of drug 
simvastatin working standard into 100mL volumetric 
flask, and about 70 mL of diluents, sonicate to 
dissolve, dilute to volume with diluents and mix. 
Filter the solution through0.45µm. 
 Preparation of system suitability solution8. 
Accurately weigh and transfer about 10mg of 
working standard into 100ml volumetric flask. Add 
25mL of 0.1N HCl and 25mL of Diluent. Sonicate to 
dissolve. Keep the sample at about 80 °C. For 4 
hours. Use this solution as system suitability 
solution. 
 Preparation of placebo solution8 
Accurately weigh and transfer powdered content of 
placebo equivalent to 100mg of Drug into 100 mL 
volumetric flask. Add about 70 mL d iluent and 
sonicate for about 15 min. dilute to the volume and 
mix. Filter the solution through 0.45µm filters.  
ABSTRACT 
A simple, accurate rapid and precise RP-HPLC method has been developed and validated for determination of 
simvastatin in bulk drug. The RP-HPLC separation was achieved on Promosil C-18, (250 mm, 4.6 mm, 5µm)  using 
mobile phase buffer: methanol ph 6.8 (96: 4 v/v) at flow rate of 1.0 ml/min at ambient temperature. The retention times 
were 9.546 min. for simvastatin. Calibration plots were linear over the concentration range 1-50µg/ml. Quantification 
was achieved with photodiode array detection at 254 nm over the concentration range of 1-50 µg/ml. The method was 
validated statistically and applied successfully for the determination of simvastatin. Validation studies revealed that 
method is specific, rapid, reliable, and reproducible. The high recovery and low relative standard deviation confirm the 
suitability of the method for the routine determination of simvastatin in bulk drug.  
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Preparation of diluents: Use mobile phase as diluents  
As in Figure-2  
Mobile phase = Methanol: Buffer pH 4.0 (96:4)  
Mobile phase = Methanol: Buffer pH 4.0 (96:4) 
Table 1: Chromatographic conditions for the optimized method for Simvastatin  
S. No. Parameters Description 
1. Instrument  A HPLC instrument (Younglin  series)  with Model Acme-9000  
2. Column   Promosil C-18, (250 mm, 4.6 mm, 5µm) 
3. Mobile Phase  Mix 5ml of glacial acid in 1000ml of water. To 1000ml of 5ml glacial acetic acid solution, add 
0.94gm of 1-Hexane sulphonic acid anhydrous. Sonicate to dissolve. The mobile phase is prepared by 
mixing buffer: methanol in the ratio of 96:4 Filtered and degas it. 
4. Flow Rate  1.0 mL/minute 
5. Detection wavelength 254 nm 
6. Injection Volume  10 L 
7. Run Time  20 Minutes 
 
   
Figure 2: Representive chromatograms of standard solution of Simvastatin  
METHOD VALIDATION 
The developed method was validated according to ICH 
guidelines. Standard calibration curve were prepared in the 
mobile phase with 5 concentration ranging from 1-50 
µg/ml for simvastatin is injected in to HPLC system 
keeping the inject ion volume constant. The peak area was 
plotted against the corresponding concentration to obtain 
the calibration graphs. To study the reliability and 
suitability of developed method, recovery experiments 
were carried out at three levels 80, 100 and 120%. Known 
concentration of Commercial tablet is spiked with known 
amounts of simvastatin. At each level of the amount six 
determinations were performed and the results obtained 
were compared with expected results. Recovery for 
pharmaceutical fo rmulat ions should be within the range 
100±5%. The percent R.S.D of individual measurements 
was also determined. Precision of the assay was 
determined by repeatability (intra-day) and intermediate 
precision (inter-day) for 3 consecutive days. Three 
different concentration of simvastatin were analysed in six 
independent series in the same day (intra-day precision) 
and 3 consecutive days (inter-day precision). The 
repeatability of sample application and measurement of 
peak area for act ive compounds were expressed in terms of 
percent RSD. 
All chromatograms were examined to determine if 
compounds of interest co-eluted with each other or with 
any additional excipient peaks. Marketed formulation were 
analysed to determine the specificity of the optimized  
method in the presence of common tablet excipients . Limi 
of detection (LOD) and limit of quantitation (LOQ) were 
estimated from single to noise ratio. LOD and LOQ were 
calculated using 3.3 /s and 10 /s formulae, respectively. 
Where  the standard deviation of the peak areas and s is 
is the slope of the corresponding calibration curve. To 
evaluate robustness of HPLC method a few parameters 
included variation of flow rate, percentage of buffer in the 
mobile phase, and pH of mobile phase. 
RES ULT AND DISCUSSION  
The retention time of simvastatin was peak eluted at 9.546 
min. The peaks are well separated with a resolution of 
3.344 and Tailing 1.136. 
The mobile phase comprises of Methanol: Buffer (96:4) 
v/v at the pH 4.0 was selected as optimized mobile phase, 
because of the high purity, symmetry, proper tailing, h igh 
area and low RT value at same concentration as compared 
to other trail mobile phase. Furthermore, the stability of the 
drug in the mobile phase were also studied and result 
indicating that the drug Simvastatin was found to be stable 
during the storage time of 48 hr (Table 2). 
Linearity of the method was investigated by serially  
diluting the working standard to give a concentration range 
of 1-10 µm/ml and 20 µl from this was injected. The flow 
rate was maintained at 1 ml/min. temperature of column 
was kept ambient and the effluent was monitored at 254 
nm. Calibrat ion curve was constructed by plotting 
concentration against peak area (fig.3).  
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Table 2: Stability of the simvastatin in the optimized mobile phase 
S. N. Storage conditions  Mean area± SD (At zero hrs) SE Mean area± SD (At 48 hrs) SE 
1. Room Temperature  
 (25±0.5 
0
C) 
252952.3±2859.82 3474.9 248844.7±3650.63 2777.53 
2. Refrigerator (4±0.5 
0
C) 252952.3±2859.82 3474.9 250011.3±3653.10 2778.63 
*Concentration of drug 10µg/ml in mobile  phase. 
 
 
Figure 3: Standard Curve of Simvastatin 
The method was validated for linearity, precision, 
accuracy, specificity, limit of detection and limit of 
quantification as per ICH guidelines. All parameters are 
validated as per ICH guidelines.  
Optimum condition of mobile phases was investigated in 
the development of an HPLC method suitable for analysis 
of in the bulk drug. These included Methanol: Acetonitrile: 
Buffer (50:20:30) (% v/v), Methanol: Acetonitrile: Buffer 
(60:20:20), Methanol: buffer (50:50), Methanol: Buffer 
(70:40), Methanol: Buffer pH 4.0 (90:10), and Methanol: 
Buffer pH 4.0 (96:4).The same solvent mixture was used 
for ext raction of the drug from the formulation containing 
excip ients. The retention time of Simvastatin obtained was 
9.546 ±.234 (1). The system suitability tests for HPLC 
were carried out on freshly prepared solution of 
Simvastatin (10 µg/ml) and parameters were studied. The 
results were summarized in Table 3. 
Table 3: System sutability test for Simvastatin: 
S. No. Parameter Value 
1. Retention time, min 9.546±0.234 
2. Tailing factor 1.136±0.274 
3. Asymmetry factor 1.139±0.864 
4. Theoretical plates 5642±0.426 
5. Resolution 3.344±0.628 
Assay of tablets of Simvastatin were perfomed. Twenty 
tablets of each company of strength 5 mg, 10 mg and 20 
mg were weighed and ground to a fine powder. A quantity 
of tablet powder equivalent to 10 mg of Simvastatin was 
transferred to 10 ml volumetric flask, d issolved and diluted 
with acetonitrile and water mixture to obtain 1 mg/ml. The 
solution was sonicated for 15 minute and filtered through 
0.45 µm membrane filter. The solution was further diluted 
to obtain concentration 10 µm/ml. Peak area of the above 
prepared tablet solutions of Simvastatin were measured by 
using above mentioned chromatographic conditions and 
the amount of Simvastatin were found from regression 
equation (Table 4) &Recovery study (Table 5). 
Table 4: Results of Analysis of Commercial Tablets of Simvastatin  
Tablet  
Formulation 
Label claim(mg) % Label claim estimated* (Mean ± 
S .D.) 
% Coeff. Of Variation Standard  error 
I(SIM) 5 99.435 ± 1.243 1.365 0.514 
II(SIMCARD) 10 99.754 ± 1.509 1.523 0.625 
III (SIMCHOL) 20 99.246 ±1.427 1.305 0.613 
*Average of six determinations 
Table 5: Recovery Studies of Commercial Tablets of Simvastatin  
Tablet 
Formulation 
Label claim 
(mg) 
Drug added 
(mg) 
% Label claim 
estimated* (Mean ± S .D.) 
% Coeff. of 
Variation 
Standard error 
I(SIM) 5 2.5 99.316 ± 1.513 1.496 0.743 
II(SIMCARD) 10 5 99.514 ± 1.397 1.432 0.574 
III (SIMCHOL) 20 10 99.288 ±0.863 0.798 0.465 
*Average of six determinations 
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The linear regression date showed a good linear 
relationship over the concentration range of 1-50 µg/ml as 
summarized in Tab le 6. The limit of detection (LOD) and 
the limit of quantification(LOQ) of the drug were found by 
scanning the solution of Simvastatin having different lower 
concentrations and the LOD and LOQ were found to be 
0.5 and 1 µg/ml indicates that method is sensitive (Table 
6). The intraday and interday precision were determined by 
analyzing standard solution of Simvastatin at three 
different concentration levels (6, 8, 10 µg/ml). The % RSD 
for intraday and interday precision was found to be 0.257 –  
0.712% and 0.480-1.080% respectively which indicate that 
method is precise (Tab le 6).  
Table-6: Stastiscal Data & Regression Equation for 
Simvastatin 
S. 
N. Parameter Value 
1. λmax (nm) 254 
2. Beer’s range(μg/ml)  5-40 
3. Molar absorbtivity    (l/mol/cm) 4.327 × 104 
4.  Correlation coefficient (r2) 0.999 
5.  Regression equation Y=0.70230X-4420 
6. Intercept (a) 04420 
7.  Slope (b) 0.70230 
8. Limit of detection (LOD μg/ml)  0.126 
9. Limit of quantification(LOQ   μg/ml)  0.406 
10. Linearity 1 – 50  
11. Accuracy% 99.16 to 101.24 
12. Repeatability (RSD, %, n=6) 0.195 
13. Precision (RSD, %), Interday (n=6) 0.480-1.080% 
14. Intraday (n=6) 0.257 – 0.712%   
Repeatability of the method was studied by injecting 10 
µg/ml solution of Simvastatin for six times and peak area 
was measured and % RSD was calculated which was 
found to be 0.195 shows repeatability of the method (Table 
6). Accuracy of the method was evaluated by standard 
addition method in which appropriate port ion of stock 
solutions of Simvastatin were spiked into blank placebo 
matrix to produce concentrations of 80 100 and 120% of 
theoretical concentration. The mean recovery of spiked 
samples obtained was in range of 99.16 to 101.24 reveals 
no interference of excip ients and shows that method is 
accurate (Table 6).  
The proposed validated method was successfully applied 
to determine Simvastatin in tablet form. The results 
obtained for tablets of Simvastatin were comparable with 
the corresponding labeled amounts (0.5 mg/tab) (table 4). 
Robustness of the method was estimated by changing the 
mobile phase composition (3±3), wavelength ±1 nm, 
injection  volume (20±2µl), column temperature (40±3
0
) 
and RSD values for all these changes calculated were less 
than 2 indicate that proposed method is robust. The 
proposed RP-HPLC method was accurate, precise, 
sensitive and rapid. The method also can be extended for 
the routine analysis of Simvastatin in tablet dosage form.  
CONCLUS ION  
It is thus concluded that the proposed method is new, 
simple, cost effective, accurate, safe, free from pollution 
and precise and can be successfully employed in the 
routine analysis of these drugs in pharmaceutical dosage 
forms. The proposed method shall prove equally effective 
to analyze Simvastatin in the corresponding drug sample 
and may prove to be of great importance in pharmaceutical 
analysis. 
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